Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Stuttering Market to Register Stunning Growth at a CAGR of 13.4% by 2034 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

30 May, 2024, 09:30 GMT

Share this article

Share toX

Share this article

Share toX

The anticipated introduction of new therapeutic options could lead to an expansion of the market for stuttering treatment during the forecast period. This growth may be fueled by factors such as an increase in the number of diagnosed cases of stuttering, facilitated by improved diagnostic techniques, and advancements in managing and treating the condition more effectively. 

LAS VEGAS, May 30, 2024 /PRNewswire/ -- DelveInsight's Stuttering Market Insights report includes a comprehensive understanding of current treatment practices, stuttering emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Stuttering Market Report

  • According to DelveInsight's analysis, the market size for stuttering was found to be USD 40 million in 2023 and it is further expected to rise by 2034.
  • According to estimations by DelveInsight, the total prevalent cases of stuttering across the 7MM stood at roughly 4 million, with nearly 885K diagnosed prevalent cases reported in 2023.
  • Among the 7MM, the US accounted for approximately 47%, EU4 and the UK for nearly 38%, and Japan for around 15% of the total diagnosed prevalent cases of stuttering in 2023; these cases are expected to increase by 2034 due to improved diagnostic methods, leading to more accurate identification and reporting of stuttering cases globally. 
  • Leading stuttering companies such as Emalex Bioscience, and others are developing novel stuttering drugs that can be available in the stuttering market in the coming years.
  • The promising stuttering therapies in the pipeline include Ecopipam (EBS-101), among others.
  • Ecopipam has the potential to revolutionize stuttering treatment, expected to launch in 2026 in the US offering a first-mover advantage in the market.

Discover which therapies are expected to grab the major stuttering market share @ Stuttering Market Report

Stuttering Overview

Childhood-onset fluency disorder, commonly referred to as stuttering or stammering, is a prevalent speech issue influenced by various factors. It results in an interruption of smooth verbal expression, characterized by involuntary repetitions or prolongations of sounds or syllables, either audible or silent. These disruptions typically happen beyond the speaker's control and may be accompanied by additional physical movements or negative emotions like fear, embarrassment, or frustration. Stuttering is recognized by recurrent instances of prolonged sounds, repeated syllables, or interruptions in speech flow, occurring at various levels of speech, from individual sounds to entire words or phrases. 

Diagnosis of stuttering is usually conducted by a speech-language pathologist (SLP), a professional trained in assessing and treating voice, speech, and language disorders. The evaluation involves examining the child's case history, analyzing their stuttering patterns, assessing their speech and language skills, and understanding how stuttering impacts their life. When assessing young children for stuttering, an SLP aims to determine whether the stuttering behavior is likely to persist or resolve. Factors considered include family history of stuttering, duration of stuttering (six months or longer), and the presence of other speech or language difficulties.

Stuttering Epidemiology Segmentation

The stuttering epidemiology section provides insights into the historical and current stuttering patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The stuttering market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalent Cases of Stuttering
  • Total Diagnosed Prevalent Cases of Stuttering
  • Gender-Specific Diagnosed Prevalent Cases of Stuttering

Stuttering Treatment Market 

Though a definitive cure for stuttering has yet to be discovered, there exist numerous treatment options tailored to individual needs, such as age and communication objectives. Collaboration with a speech-language pathologist is imperative for determining the most suitable course of action. While around 75% of children naturally outgrow stuttering, the remaining 25% may experience it as a lifelong challenge. Therapeutic interventions aim to alleviate the anxiety associated with stuttering and equip individuals with strategies to reduce speech disruptions, including speaking at a slower pace and managing breathing patterns. Technological aids, such as electronic devices, may also aid in improving fluency. Furthermore, Support Groups offer invaluable assistance to children, teenagers, and adults coping with stuttering, fostering positive attitudes toward speech and stuttering. These groups often complement formal speech therapy by concentrating on speech behaviors.

Medications like alprazolam, citalopram, and clomipramine have been noted to alleviate stuttering in specific cases. In Germany, parents worried about their child's stuttering typically turn to medical professionals such as pediatricians, pediatric audiologists, and ear, nose, and throat specialists. These professionals may prescribe medication and refer the child to a speech-language pathologist, usually in private practice or occasionally to a specialized stuttering treatment facility. Similarly, adults seeking treatment for stuttering also start by consulting a physician to obtain a medical referral, which is necessary for health insurance coverage.

To know more about stuttering treatment guidelines, visit @ Stuttering Management 

Stuttering Pipeline Therapies and Key Companies

Not many companies are working towards this indication, however, some market key players, Emalex Bioscience (Ecopipam (EBS-101)), and others are developing drugs for the treatment of stuttering. 

Ecopipam (EBS-101), a novel experimental medication, is under investigation as a pioneering treatment for childhood-onset fluency disorder (stuttering) in pediatric patients and Tourette syndrome (TS) in adults. The repetitive and compulsive behaviors linked to stuttering and TS may involve D1 receptor super-sensitivity, which Ecopipam targets by selectively inhibiting dopamine's effects at the D1 receptor. In 2022, the drug candidate concluded a Phase II trial in adults with childhood-onset fluency disorder (stuttering), but there have been no subsequent developments reported.

The anticipated launch of this emerging therapy for stuttering is poised to transform the market landscape in the coming years. As this cutting-edge therapy continues to mature and gain regulatory approval, it is expected to reshape the stuttering market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Learn more about the FDA-approved drugs for stuttering @ Drugs for Stuttering Treatment 

Stuttering Market Dynamics

The dynamics of the stuttering market are expected to change in the coming years. Growing research activities in the field show rising concerns about the seriousness of the speech disorder, with no approved drug for stuttering globally, presenting an opportunity for product-developing companies. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the stuttering market in the 7MM.

However several factors may impede the growth of the stuttering market. Many patients, not realizing the need for treatment, learn to live with their stuttering problem throughout their life, thereby weakening the stuttering market, as those who stutter are advised against pharmacologic therapy, posing a threat to the stuttering market due to the likelihood of patients avoiding medication even if it becomes available.

Moreover, stuttering treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the stuttering market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the stuttering market growth.

Stuttering Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Stuttering Market CAGR

13.4 %

Stuttering Market Size in 2023

USD 40 Million

Key Stuttering Companies

Emalex Bioscience, and others

Key Pipeline Stuttering Therapies

Ecopipam (EBS-101), and others

Scope of the Stuttering Market Report

  • Therapeutic Assessment: Stuttering current marketed and emerging therapies
  • Stuttering Market Dynamics: Key Market Forecast Assumptions of Emerging Stuttering Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Stuttering Market Access and Reimbursement

Discover more about stuttering drugs in development @ Stuttering Clinical Trials

Table of Contents

1.

Stuttering Key Insights

2.

Stuttering Report Introduction

3.

Stuttering Overview at a Glance

4.

Stuttering Executive Summary

5

Stuttering Key Events

6

Epidemiology and Market Forecast Methodology

6.

Disease Background and Overview

7.

Stuttering Treatment and Management

8.

Stuttering Guidelines

9.

Stuttering Epidemiology and Patient Population

10.

Patient Journey

11.

Key Endpoints in Stuttering 

12.

Stuttering Marketed Drugs

13.

Stuttering Emerging Drugs

14.

7MM Stuttering Market Analysis

15.

Market Access and Reimbursement

16.

KOL Views

17.

Unmet Needs

18.

SWOT Analysis

19.

Appendix

20.

DelveInsight Capabilities

21.

Disclaimer

22.

About DelveInsight

Related Reports

Stuttering Epidemiology Forecast

Stuttering Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted stuttering epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Apraxia Market

Apraxia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key apraxia companies, including Arrowhead Pharmaceuticals, Novartis, Alnylam Pharmaceuticals, LIB Therapeutics, among others.

Ataxia Pipeline

Ataxia Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ataxia companies, including Retrotope, Reata Pharmaceuticals, PTC Therapeutics, Metro International Biotech, LLC, Design Therapeutics, Larimar Therapeutics, Minoryx Therapeutics, EryDel, Biogen, Matrix Biomed, IntraBio, Biohaven Pharmaceuticals, Inc., Stealth BioTherapeutics Inc., Acasti Pharma, Seelos Therapeutics, Kissei Pharmaceutical, Vico Therapeutics, Q-State Biosciences, Locanabio, Lexeo Therapeutics, Voyager Therapeutics, CRISPR Therapeutics, Capsida Biotherapeutics, AavantiBio, StrideBio, Wave Life Sciences, REPROCELL, SHIONOGI & Co., CORESTEM, Blade Therapeutics, Exicure, Lacerta Therapeutics, Healx Ltd., Uniqure, Ionis Pharmaceuticals, Jupiter Neurosciences, among others.

Ataxia Market

Ataxia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ataxia companies, including Retrotope, Reata Pharmaceuticals, PTC Therapeutics, Metro International Biotech, LLC, Design Therapeutics, Larimar Therapeutics, Minoryx Therapeutics, EryDel, Biogen, Matrix Biomed, IntraBio, Biohaven Pharmaceuticals, Inc., Stealth BioTherapeutics Inc., Acasti Pharma, Seelos Therapeutics, Kissei Pharmaceutical, Vico Therapeutics, Q-State Biosciences, Locanabio, Lexeo Therapeutics, Voyager Therapeutics, CRISPR Therapeutics, Capsida Biotherapeutics, AavantiBio, StrideBio, Wave Life Sciences, REPROCELL, SHIONOGI & Co., CORESTEM, Blade Therapeutics, Exicure, Lacerta Therapeutics, Healx Ltd., Uniqure, Ionis Pharmaceuticals, Jupiter Neurosciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Medical Equipment

Medical Equipment

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.